BioMarin acquires Amicus Therapeutics

BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics Inc. in a transaction valued at approximately $4.8 billion. The acquisition, announced on December 19, 2025, is structured as an all-cash deal. This strategic move aims to enhance BioMarin's cash flow stability while it continues to focus on its existing pipeline, including its key growth driver, Voxzogo, a treatment for achondroplasia, a genetic bone disorder.

BioMarin, a biotech firm with a significant presence in rare disease treatments, will integrate Amicus's operations, which are headquartered in Princeton, New Jersey. The deal remains subject to customary closing conditions, including regulatory approvals. As of the latest available data, the acquisition is pending completion.

The strategic rationale for the acquisition centers on complementing BioMarin's existing portfolio with Amicus’s capabilities in rare metabolic diseases, potentially accelerating growth and synergies across both companies’ pipelines. BioMarin intends to leverage Amicus’s assets to bolster its long-term revenue streams and enhance its competitive positioning within the biotechnology sector.

This acquisition occurs against the backdrop of an evolving biotechnology landscape, where consolidations are becoming a prevalent strategy to achieve scale and increase R&D capabilities. While BioMarin's current flagship product, Voxzogo, continues to show promise as a near-term revenue driver, the integration with Amicus allows for diversification and reduces dependency on a single product line.

Going forward, the key focus will be navigating regulatory approvals and achieving operational integration. The successful completion of this transaction will be pivotal for BioMarin in the coming quarters as it aims to leverage the expanded portfolio to reinforce its market position.